

PATENT
1718-0208P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Martin QUIBELL et al. Conf.:
Appl. No.: NEW Group:
Filed: October 3, 2003 Examiner:
For: CYSTEINE PROTEASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 3, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

<u>U.S. Appl. No(s).</u>	<u>U.S. Filing Date(s)</u>
10/042,565	November 16, 2001
10/015,186	November 16, 2001

<u>International Appl No.</u>	<u>International Filing Date</u>
PCT/GB00/01894	May 18, 2000

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Leonard R. Svensson, #30,330

LRS/SWG/sbp
1718-0208P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)
☐ References
☒ Foreign Search Report
☐ Other:

(Rev. 04/29/03)

Form PTO-1449					ATTY DOCKET NO. 1718-0208P		APPLICATION NO. NEW		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)					APPLICANT Martin QUIBELL et al.				
					FILING DATE October 1, 2003		GROUP		
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
	US								
FOREIGN PATENT DOCUMENTS									
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
	WO	98/50533	A1	1998-11-12	PCT			YES	NO
	WO	00/29408	A1	2000-05-25	PCT				
	WO	00/49011	A1	2000-08-24	PCT				
	WO	99/53039	A1	1999-10-21	PCT				
	WO	00/69855	A1	2000-11-23	PCT				
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	HANZLIK R P et al. "Vinylogous amino acid esters: a new classs of inactivators...", Journal of Medicinal Chemistry, Vol 27, No 6, June 1, 1984, pages 711-712. XP002037365.								
	KATUNUMA, N et al., FEBS Letters, Vol. 458, pages 6-10.								
	VILLADANGOS, J.A. et al., Immunol. Rev., Vol. 172, 1999, pages 109-120, MEDLINE abstract 10631941.								
	SAEGUSA, K et al., Clin. Invest., Vol. 110, 2002, pages 361-9, MEDLINE abstract 12163455								
EXAMINER					DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									